Cancer diagnosis is important, and the early diagnosis of cancers could predict a more successful treatment. The proteomic studies emerged to be useful in combined analyses of samples from patients and provide more accurate diagnosis when compared to the single-factor-based diagnosis. In recent years, cancer detection with surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS) is flourishing and brought significant progress in this area. This paper summarizes some recent results with this technique for cancer diagnosis.
1. Introduction
Cancer diagnosis is important, and the early diagnosis of cancers could predict a more successful treatment. The accurate diagnosis of cancers before the appearance of symptoms often relies on the identification of reliable biomarkers. Further, these biomarkers reflecting the progression of cancers suggest the etiology of the disease. Proteomics technology has emerged to be important tools in cancer diagnosis and evaluation tools during treatment through the analyses of changes in cancer biomarkers. The fact that people have identified diverse biomarkers during the development and progression of different cancers suggested that the specificity and abundance of many small proteins could reflect the current state of cancer progression, and even predict the treatment efficacy. From serum, saliva, urine, and so forth, people could acquire the complete proteome that reflect the dynamic proteomics of the patients with high accuracy; and proteomic analyses permit the combined comparison of several biomarkers at the same time, which could finally bring convincing results. This included two-dimensional gel electrophoresis (2-DE), one-or two-dimensional liquid chromatographic (LC-MS), and surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS). In the present paper we review the progresses achieved in using SELDI-TOF MS technology for cancer biomarker profiling and detection.
2. Introduction to SELDI-TOF MS
The SELDI-TOF MS technique was firstly introduced in 1993 [1] and was commercialized by Ciphergen Biosystems in 1997 as the ProteinChip system. SELDI-TOF-MS is one type of variation of matrix-assisted laser desorption/ionization (MALDI) that uses a target modified to reach biochemical affinity with the sample proteins. The differences between the two techniques are the following. In MALDI, the sample is mixed with the matrix molecule in solution, and a small amount of the mixture was deposited on a surface to dry. This made the sample and matrix cocrystallized after the solvent evaporated. On the other hand, in SELDI, the mixture is spotted on a surface modified with a chemical functionality such as binding affinity. Without being dried, some proteins in the samples would bind to the modified surface, while the others were washed off. Then the matrix is applied to the surface for crystallization with the sample peptides. In the binding and washing off steps the surface-bound proteins are left for analyses. Samples spotted on an SELDI surface were typically analyzed with time-of-flight mass spectrometry (TOF-MS) [2]. A laser-ionized peptides from crystals of the sample and matrix mixture. These ions were then accelerated through an electric field and down into the flight tube. Finally, the detector would measure ions as they reach the end of the tube (Figure 1). The mass-to-charge ratio of each ion could be determined from the length of the tube, the kinetic energy given to ions by the electric field, and the time taken to travel the length of the tube. Some surfaces that were normally adopted include CM10 (weak-positive ion exchange), H50 (hydrophobic surface, similar to C6-C12 reverse phase chromatography), IMAC30 (metal-binding surface), and Q10 (strong anion exchanger). Surfaces can also be modified or functionalized with antibodies, other proteins with proper binding properties, or even DNA.
After the samples were dried, a laser-ionized peptides from crystals of the sample and matrix mixture. Then, these ions were accelerated through an external electric field and down into the flight tube. Finally, the detector would measure ions as they reach the end of the tube with software readout the data.
3. Body Fluids as Important SELDI-TOF MSSamples
One of the key features of SELDI-TOF MS is the little requirement of sample purification or protein separations before the MS analyses. With high sensitivity to low-molecular-weight proteins (less than 15 kda), SELDI-TOF MS could detect some biomarkers that were neglected in other proteomic analyses such as 2D-gels [3, 4]. In finding samples for SELDI-TOF MS analysis, both tissue extracts and body fluids could be used. In past studies, the analyzed body fluids include plasma, serum, urine, saliva, amniotic fluid, cerebrospinal liquid, bronchoalveolar wash out, tears, and nipple aspirate fluid [5–23]. Among these choices, serum, urine, saliva, and plasma were most widely used.
The challenge that biomarker proteins only take a very small proportion in total plasma proteins—less than one percent suggested that MS is more suitable in cancer detection in compared to other less sensitive approaches [24]. Moreover, the levels of proteins could vary according to the environmental stress, codiseased disorders or previous drug treatments [24, 25]. Sometimes, the proteins were modified or cleaved by enzymes, which further decreased the amount of biomarkers for detection in body fluids. All these difficulties suggested that cancer detection should adopt SELDI-TOF MS technique with high sensitivity and without the need of previous protein purification from samples. Consistently, it was showed that the highly abundant proteins in the serum such as albumin and immunoglobulin could be well separated from potential markers without causing any inference [16, 26–29].
4. Cancer Diagnosis
Many types of cancers could be and have been diagnosed with SELDI-TOF MS technology. It is possible to read the different peaks in samples from control and patients, as shown in Figure 2. In the paragraphs below, we selected ovarian cancer, breast cancer, prostate cancer, and hepatocellular cancer as examples showing how the new technique promoted the diagnosis of these cancers.
Samples from control and colorectal cancer patients showed different peaks in proteomics spectrum. Some changes were highlighted.
4.1. Ovarian Cancer
It was found that early diagnosed (phase I) ovarian cancer patients have the 5-year survival rates more than 90%, which is 35% in most middle-late phase cases [30, 31]. Some studies tried to diagnose phase I patients accurately. For instance, one study adopted C16 surface chips with SELDI-TOF MS in analyzing 50 patient cases and found a different pattern of proteome including five peaks at 534, 989, 21 11, 2251, and 2465, respectively, [31, 32]. In most of these studies, the method could reach diagnosis accuracy, sensitivity, and specificity of more than 99%, especially when combined with improved statistical methods [33–40]. Taken together, SELDI-TOF MS could be an important and very accurate tool in diagnosing ovarian cancer patients, both in early and advanced stages.
4.2. Breast Cancer
X-ray examination was now routinely adopted for women aged more than 40 years old however, the accuracy is only around 50%. There were some available biomarkers in serum for breast cancer diagnosis, such as CA15.3, but with low sensitivity (23%) and specificity (69%) [41, 42]. In one study that combined IMAC-Ni2+ chip with SELDI-TOF MS, the authors showed three protein spectrum peaks at 4.3, 8.1, and 8.92 kda, respectively, combined analyses with the three peaks in 169 cases (103 patient cases) and showed the diagnosis sensitivity 93% and specificity 96% [43]. In other studies, many other potential biomarkers have been identified, and reached high accuracy in diagnosis [44–55], and combined analyses of these biomarkers could further improve the sensitivity and specificity.
4.3. Prostate Cancer
Prostate-specific antigen (PSA) has been widely used in prostate cancer diagnosis with relatively high sensitivity but quite low specificity [56, 57] −95% and 18%, respectively, as shown in one previous study [58]. Many studies have adopted SELDI-TOF MS to find better biomarker for early prostate cancer diagnosis [59–68]. One study compared serum samples from prostate cancer patients and patients with other prostate diseases for SELDI-TOF MS analyses; they found several biomarkers including PC1, PC2, and PC3, with higher sensitivity when compared to PSA-based diagnosis in the study involved in more than 300 cases [69]. The serum-based proteomic analysis would become one of the major diagnosis tools for prostate cancer in the future.
4.4. Hepatocellular Cancer
Hepatocellular cancer (HCC) is the most common primary malignant tumor of the liver. Primary liver cancer accounts for less than 1% of all cancers in states, however, in past decades, this increased due to a large pool of people with longstanding hepatitis C virus infection. This is even worse in China and many developing countries. The detection of HCC could be very difficult, as most patients onset without any symptoms. Ultrasound detection and alpha-fetoprotein (AFP) in the serum were used in past studies [71, 72]. However, it should be noted that serum AFP levels were normal in 40% patients with <2 cm (in diameter) hepatocellular carcinoma and in 28% of those with tumors 2 to 5 cm in diameter. Additionally, not all hepatocellular carcinomas secrete AFP such as the Fibrolamellar type. The AFP levels could also be elevated in pregnancy, other gonadal originated tumors, and even in acute or chronic liver diseases (CLD) without tumor. All of these weakened the sensitivity and specificity of AFP as serum biomarkers for HCC.
SELDI-TOF MS have been adopted to find new biomarkers for HCC diagnosis [71, 73–82]. In another study, the authors adopted the multidimensional separated statistics in analyzing the proteomics data and showed diagnosis specificity of 90% and sensitivity of 92% in separating HCC out of CLD, which could not be reached with AFP examination [83]. More interestingly, their works showed the proteomics between subtypes of HCC: the progressive one and the metastasis one. All these data could provide new hopes for accurate and early detection of HCC in patients or people living in areas with hepatitis B and C virus infection.
It should be noted that in practice, the combined use of several potential biomarkers could greatly increase the specificity and sensitivity of cancer diagnosis [46, 84–88]. It is now convenient to set up the diagnostic tree with software, and the diagnosis automatically follows. These selected combinations could be considered as a group of biomarkers representing the etiology of cancer in given population, which might provide some rationale bases for therapeutic developments.
5. Summary
In this paper, we briefly summarized the recent progresses achieved in cancer detection and diagnosis with SELDI-TOF MS technique. The use of body fluids and tissue extracts with low proteins content as samples in this technology is superior to many other available proteomic approaches. Moreover, SELDI-TOF MS is very sensitive and reliable in repeated tests (Figure 3) [70]. It should also be noted that SELDI-TOF-MS could also contribute to the ongoing human proteome studies, as proposed for the total proteins in the serum [2, 29, 89]. When combined with radiological data, this could finally bring patients new hopes in the early detection of the tumors inside even before the onset of symptoms. For instance, the detection of specific changes in one protein might point out the potential regions of cancer genesis and, therefore, suggest the regions of interest for radiologist; also, when unknown tissues were identified in the radiological report, the accurate SELDI-TOF-MS could be used to verify the existence of a tumor. We believe that SELDI-TOF-MS would become one of the most powerful tools in early cancer diagnosis in coming days.
This represented the reproducibility of four separate analyses from the healthy controls of blood type O, suggesting the high reliability of SELDI-TOF MS in serum sample analyses [70].
Acknowledgments
The work was funded by Zhejiang Medicine, Health, and Science Grant no. 2010KYB127, Educational Commission of Zhejiang Province Grant no. Y201016269, Science and Technology Planning Project of Hangzhou 20100633B13, and Zhejiang Gong Yi Xing Technology Application Project Grant no. 2011C33SA810001. The author also thanks the Department of Laboratory Medicine, the Affiliated Taizhou Municipal Hospital and Taizhou Medical College for supports.
HutchensT. W.YipT. T.New desorption strategies for the mass spectrometric analysis of macromolecules19937576580ZhouM.VeenstraT. D.Mass spectrometry: m/z 1983–200820084456676702-s2.0-4324910365510.2144/000112791TangN.TornatoreP.WeinbergerS. R.Current developments in SELDI affinity technology200423134442-s2.0-014214322710.1002/mas.10066WrightG. L.SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis2002265495632-s2.0-003685551910.1586/14737159.2.6.549AbramovitzM.Leyland-JonesB.A systems approach to clinical oncology: focus on breast cancer200642-s2.0-3364623029610.1186/1477-5956-4-55ArdekaniA. M.LiottaL. A.PetricoinE. F.Clinical potential of proteomics in the diagnosis of ovarian cancer2002243123202-s2.0-0036020072BertucciF.BirnbaumD.GoncalvesA.Proteomics of breast cancer: principles and potential clinical applications2006510177217862-s2.0-3375061955710.1074/mcp.R600011-MCP200ChaurandP.SchwartzS. A.CaprioliR. M.Assessing protein patterns in disease using imaging mass spectrometry2004322452522-s2.0-414307080110.1021/pr0341282ChaurandP.SchwartzS. A.ReyzerM. L.CaprioliR. M.Imaging mass spectrometry: principles and potentials2005331921012-s2.0-1344430450310.1080/01926230590881862CiordiaS.de los RíosV.AlbarJ. P.Contributions of advanced proteomics technologies to cancer diagnosis2006885665802-s2.0-3374908073810.1007/s12094-006-0062-4CombaretV.BergeronC.BréjonS.IaconoI.PerolD.NégrierS.PuisieuxA.Protein chip array profiling analysis of sera from neuroblastoma patients20052281-291962-s2.0-2394452379010.1016/j.canlet.2004.12.053Del BoccioP.UrbaniA.Homo sapiens proteomics: clinical perspectives20054144794822-s2.0-33646834486DrakeR. R.WhiteK. Y.FullerT. W.IgweE.ClementsM. A.NyalwidheJ. O.GivenR. W.LanceR. S.SemmesO. J.Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease20097269079172-s2.0-6765124991310.1016/j.jprot.2009.01.007HendersonN. A.SteeleR. J. C.SELDI-TOF proteomic analysis and cancer detection2005363833902-s2.0-29244462499HerringK. D.OppenheimerS. R.CaprioliR. M.Direct tissue analysis by matrix-assisted laser desorption ionization mass spectrometry: application to kidney biology20072765976082-s2.0-3654908596110.1016/j.semnephrol.2007.09.002KarpovaM. A.MoshkovskiiS. A.ToropyginI. Y.ArchakovA. I.Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives20107335375512-s2.0-7214908795410.1016/j.jprot.2009.09.011KatzJ. E.MallickP.AgusD. B.A perspective on protein profiling of blood20059644774822-s2.0-2414450295510.1111/j.1464-410X.2005.05669.xMartinD. B.NelsonP. S.From genomics to proteomics: techniques and applications in cancer research20011111S60S652-s2.0-003550108710.1016/S0962-8924(01)02123-7MassionP. P.CaprioliR. M.Proteomic strategies for the characterization and the early detection of lung cancer200619102710392-s2.0-3424788203210.1097/01243894-200611000-00019MisekD. E.PatwaT. H.LubmanD. M.SimeoneD. M.Early detection and biomarkers in pancreatic cancer2007510103410412-s2.0-37049033867ShauH.ChandlerG. S.WhiteleggeJ. P.GornbeinJ. A.FaullK. F.ChangH. R.Proteomic profiling of cancer biomarkers2003221471582-s2.0-3242749915WulfkuhleJ. D.PaweletzC. P.SteegP. S.PetricoinE. F.LiottaL.Proteomic approaches to the diagnosis, treatment, and monitoring of cancer200353259682-s2.0-0141757376XiaoZ.PrietoD.ConradsT. P.VeenstraT. D.IssaqH. J.Proteomic patterns: their potential for disease diagnosis20052301-2951062-s2.0-1234427290210.1016/j.mce.2004.10.010AndersonN. L.AndersonN. G.The human plasma proteome: history, character, and diagnostic prospects20021118458672-s2.0-0001644020SeibertV.EbertM. P. A.BuschmannT.Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery20054116262-s2.0-1944438763210.1093/bfgp/4.1.16Fink-RetterA.CzerwenkaK.Gschwantler-KaulichD.HudelistG.PischingerK.ManaviM.KubistaE.SingerC. F.Proteomics in mammary cancer research20093066356392-s2.0-70949091352GarrisiV. M.AbbateI.QuarantaM.MangiaA.TommasiS.ParadisoA.SELDI-TOF serum proteomics and breast cancer: which perspective?2008567797852-s2.0-5814914991910.1586/14789450.5.6.779SomasundaramK.NijagunaM. B.KumarD. M.Serum proteomics of glioma: methods and applications2009976957072-s2.0-7035004924410.1586/erm.09.52WhelanL. C.PowerK. A. R.McDowellD. T.KennedyJ.GallagherW. M.Applications of SELDI-MS technology in oncology2008125153515472-s2.0-5424909750810.1111/j.1582-4934.2008.00250.xLinC. Y.TsuiK. H.YuC. C.YehC. W.ChangP. L.YungB. Y. M.Searching cell-secreted proteomes for potential urinary bladder tumor markers2006615438143892-s2.0-3374778149310.1002/pmic.200600066PetricoinE. F.ArdekaniA. M.HittB. A.LevineP. J.FusaroV. A.SteinbergS. M.MillsG. B.SimoneC.FishmanD. A.KohnE. C.LiottaL. A.Use of proteomic patterns in serum to identify ovarian cancer200235993065725772-s2.0-003711683210.1016/S0140-6736(02)07746-2PetricoinE. F.LiottaL. A.Mass spectrometry-based diagnostics: the upcoming revolution in disease detection20034945335342-s2.0-003738123610.1373/49.4.533CadronI.Van GorpT.AmantF.VergoteI.MoermanP.WaelkensE.DaemenA.Van De PlasR.De MoorB.ZeillingerR.The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles2009294103910462-s2.0-64949109360LeiserowitzG. S.LebrillaC.MiyamotoS.AnH. J.DuongH.KirmizC.LiB.LiuH.LamK. S.Glycomics analysis of serum: a potential new biomarker for ovarian cancer?20081834704752-s2.0-4344912915710.1111/j.1525-1438.2007.01028.xTangK. L.LiT. H.XiongW. W.ChenK.Ovarian cancer classification based on dimensionality reduction for SELDI-TOF data2010112-s2.0-7794941345610.1186/1471-2105-11-109109WangJ.ZhangX.GeX.GuoH.XiongG.ZhuY.Proteomic studies of early-stage and advanced ovarian cancer patients200811111111192-s2.0-5204909343110.1016/j.ygyno.2008.06.031WuS. P.LinY. W.LaiH. C.ChuT. Y.KuoYU. L.LiuH. S.SELDI-TOF MS profiling of plasma proteins in ovarian cancer200645126322-s2.0-33645744573YuJ. S.OngarelloS.FiedlerR.ChenX. W.ToffoloG.CobelliC.TrajanoskiZ.Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data20052110220022092-s2.0-1954439446010.1093/bioinformatics/bti370ZhangH.KongB.QuX.JiaL.DengB.YangQ.Biomarker discovery for ovarian cancer using SELDI-TOF-MS2006102161662-s2.0-3374491578710.1016/j.ygyno.2005.11.029ZhuY.WuR.SanghaN.YooC.ChoK. R.SheddenK. A.KatabuchiH.LubmanD. M.Classifications of ovarian cancer tissues by proteomic patterns2006621584658562-s2.0-3375109877010.1002/pmic.200600165LumachiF.BassoS. M. M.Serum tumor markers in patients with breast cancer2004459219312-s2.0-5444271133SafiF.KohlerI.RottingerE.BegerH. G.The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer: a comparative study with carcinoembryonic antigen19916835745822-s2.0-0026015241LiJ.ZhangZ.RosenzweigJ.WangY. Y.ChanD. W.Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer2002488129613042-s2.0-0036324715CelisJ. E.jec@cancer.dkGromovP.CabezónT.MoreiraJ. M. A.AmbartsumianN.SandelinK.RankF.GromovaI.Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment20043432734410.1074/mcp.M400009-MCP200DaviesG. F.RossA. R.ArnasonT. G.JuurlinkB. H. J.HarknessT. A. A.Troglitazone inhibits histone deacetylase activity in breast cancer cells201028822362502-s2.0-7484909802610.1016/j.canlet.2009.07.011FanY.WangJ.YangY.LiuQ.FanY.YuJ.ZhengS.LiM.WangJ.Detection and identification of potential biomarkers of breast cancer2010136124312542-s2.0-7794943000810.1007/s00432-010-0775-1GastM. C. W.van GilsC. H.WesselsL. F. A.HarrisN.BonfrerJ. M. G.RutgersE. J. T. H.SchellensJ. H. M.BeijnenJ. H.Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS20092212052132-s2.0-6824915261510.3892/or_00000426HeQ.ZhangS. Q.ChuY. L.JiaX. L.ZhaoL. H.WangX. L.Separation and identification of differentially expressed nuclear matrix proteins in breast carcinoma forming201049176842-s2.0-7664911911910.3109/02841860903287213HodgkinsonV. C.EagleG. L.DrewP. J.LindM. J.CawkwellL.Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status2010294113242-s2.0-7795302297010.1016/j.canlet.2010.01.036ChouchaneL.KabbageM.ChahedK.HamritaB.GuillierC. L.TrimecheM.RemadiS.HoebekeJ.Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry2008200812-s2.0-4294916999810.1155/2008/564127564127LaiT. C.ChouH. C.ChenY. W.LeeT. R.ChanH. T.ShenH. H.LeeW. T.LinS. T.LuY. C.WuC. L.ChanH. L.Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis201093130213222-s2.0-7794981734210.1021/pr900825tLattováE.TomanekB.BartusikD.PerreaultH.N-Glycomic changes in human breast carcinoma MCF-7 and T-lymphoblastoid cells after treatment with Herceptin and Herceptin/Lipoplex201093153315402-s2.0-7794980851810.1021/pr9010266RauserS.MarquardtC.BalluffB.DeiningerS. O.AlbersC.BelauE.HartmerR.SuckauD.SpechtK.EbertM. P.SchmittM.AubeleM.HǒflerH.WalchA.Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry201094185418632-s2.0-7795066116810.1021/pr901008dZeidanB. A.CutressR. I.MurrayN.CoultonG. R.HastieC.PackhamG.TownsendP. A.Proteomic analysis of archival breast cancer serum2009631411482-s2.0-67649479594ZeidanB. A.TownsendP. A.SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression20081031072-s2.0-55749102907De VisschereP.OosterlinckW.De MeerleerG.VilleirsG.Clinical and imaging tools in the early diagnosis of prostate cancer, a review201093262702-s2.0-77952852853HumphreyP. A.AndrioleG. L.Prostate cancer diagnosis201010721071122-s2.0-77953281500RoddamA. W.DuffyM. J.HamdyF. C.WardA. M.PatnickJ.PriceC. P.RimmerJ.SturgeonC.WhiteP.AllenN. E.Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis20054833863992-s2.0-2394449285210.1016/j.eururo.2005.04.015CalvanoC. D.ArestaA.IacovoneM.De BenedettoG. E.ZamboninC. G.BattagliaM.DitonnoP.RutiglianoM.BettocchiC.Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles20105149079142-s2.0-7214911670010.1016/j.jpba.2009.10.014GrossM.TopI.LauxI.KatzJ.CurranJ.TindellC.AgusD.β-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer2007137197919862-s2.0-3424749545310.1158/1078-0432.CCR-06-1156KohliM.SiegelE.BhattacharyaS.KhanM. A.ShahR.SuvaL. J.Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer2006262492582-s2.0-34248562033KyselovaZ.MechrefY.Al BatainehM. M.DobroleckiL. E.HickeyR. J.VinsonJ.SweeneyC. J.NovotnyM. V.Alterations in the serum glycome due to metastatic prostate cancer200765182218322-s2.0-3424927773910.1021/pr060664tLexanderH.PalmbergC.HellmanU.AuerG.HellströmM.FranzénBO.JörnvalH.EgevadL.Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer2006615437043802-s2.0-3374775517310.1002/pmic.200600148MobleyJ. A.LamY. W.LauK. M.PaisV. M.L'EsperanceJ. O.SteadmanB.FusterL. M.BluteR. D.TaplinM. E.HoS. M.Monitoring the serological proteome: the latest modality in prostate cancer detection.200417213313372-s2.0-3242816195RehmanI.AzzouziA. R.CattoJ. W. F.AllenS.CrossS. S.FeeleyK.MeuthM.HamdyF. C.Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study2004646123812432-s2.0-1064423166810.1016/j.urology.2004.06.063SkyttA.ThysellE.StattinP.StenmanU. H.AnttiH.WikströmP.SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer200712136156202-s2.0-3425086949410.1002/ijc.22722YoonS. J.ParkS. Y.PangP. C.GallagherJ.GottesmanJ. E.DellA.KimJ. H.HakomoriS. I.N-glycosylation status of β-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases20103611932032-s2.0-7454916618710.3892/ijo-00000490ZhouM.PrietoD. A.LucasD. A.ChanK. C.IssaqH. J.VeenstraT. D.ConradsT. P.Identification of the SELDI ProteinChip human serum retentate by microcapillary liquid chromatography-tandem mass spectrometry200659220722162-s2.0-3374830412710.1021/pr060061hLiJ.WhiteN.ZhangZ.RosenzweigJ.MangoldL. A.PartinA. W.ChanD. W.Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population20041715178217872-s2.0-304264340410.1097/01.ju.0000119823.86393.49GuoR.PanC.ShenJ.LiuC.New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry20111375135192-s2.0-7795229488810.1007/s00432-010-0899-3LeeN. P.ChenL.LinM. C.TsangF. H.YeungC.PoonR. T.PengJ.LengX.BerettaL.SunS.DayP. J.LukJ. M.Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma200983129313032-s2.0-6524910719210.1021/pr800637zZinkinN. T.GrallF.BhaskarK.OtuH. H.SpentzosD.KalmowitzB.WellsM.GuerreroM.AsaraJ. M.LibermannT. A.AfdhalN. H.Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease20081424704772-s2.0-3894914574310.1158/1078-0432.CCR-07-0586CoronaG.De LorenzoE.EliaC.SimulaM. P.AvelliniC.BaccaraniU.LupoF.TiribelliC.ColombattiA.ToffoliG.Differential proteomic analysis of hepatocellular carcinoma201036193992-s2.0-7454913808610.3892/ijo-00000479CuiJ. F.LiuY. K.ZhouH. J.KangX. N.HuangC.HeY. F.TangZ. Y.UemuraT.Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis2008148125712622-s2.0-4054913348110.3748/wjg.14.1257GengX.WangF.LiY. G.ZhuG. P.ZhangW. M.SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma20072645055082-s2.0-38549084705GoldmanR.RessomH. W.VargheseR. S.GoldmanL.BascugG.LoffredoC. A.Abdel-HamidM.GoudaI.EzzatS.KyselovaZ.MechrefY.NovotnyM. V.Detection of hepatocellular carcinoma using glycomic analysis2009155180818132-s2.0-6354911187710.1158/1078-0432.CCR-07-5261KakehashiA.KatoA.InoueM.IshiiN.OkazakiE.WeiM.TachibanaT.WanibuchiH.Cytokeratin 8/18 as a new marker of mouse liver preneoplastic lesions2010242147552-s2.0-7044951897410.1016/j.taap.2009.09.013LattováE.MckenzieE. J.GruwelM. L. H.SpicerV.GoldmanR.PerreaultH.Mass spectrometric study of N-glycans from serum of woodchucks with liver cancer20092318298329952-s2.0-6984910483710.1002/rcm.4202LiN.LongY.FanX.LiuH.LiC.ChenL.WangZ.Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues20092812-s2.0-7034925569210.1186/1756-9966-28-122122MatosJ. M.WitzmannF. A.CummingsO. W.SchmidtC. M.A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States200915522372432-s2.0-6765094524010.1016/j.jss.2008.06.008SaitoY.ObaN.NishinakagawaS.MizuguchiY.KojimaT.NomuraK.NakatsuraT.Identification of ß2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis2010235132513302-s2.0-7795083918010.3892/or-00000767TangZ.VargheseR. S.BekesovaS.LoffredoC. A.HamidM. A.KyselovaZ.MechrefY.NovotnyM. V.GoldmanR.RessomH. W.Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data2010911041122-s2.0-7364910622410.1021/pr900397nPoonT. C. W.YipT. T.ChanA. T. C.YipC.YipV.MokT. S. K.LeeC. C. Y.LeungT. W. T.HoS. K. W.JohnsonP. J.Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes20034957527602-s2.0-024241751310.1373/49.5.752LiuC.WangH.PanC.MouS.LiangY.Serum protein fingerprint of patients with gastric cancer by SELDI technology2010915229823042-s2.0-77951225092LiuJ.GuoY.FuS.YangM.SunK. L.FuW. N.Hypomethylation-induced expression of S100A4 increases the invasiveness of laryngeal squamous cell carcinoma2010234110111072-s2.0-7794948375810.3892/or-00000738LiuL. H.ShanB. E.TianZI. Q.SangM. X.AiJ.ZhangZ. F.MengJ.ZhuH.WangS. J.Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry20104868558612-s2.0-7795321267210.1515/CCLM.2010.138LiuM.LiC. F.ChenH. S.LinL. Q.ZhangC. P.ZhaoJ. L.LiuY.ZhangS. J.JinJ. C.WangL.LiuJ. R.Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls201082-s2.0-7795265231710.1186/1477-5956-8-1616LiuW.GaoX.CaiQ.LiJ.ZhuZ.LiC.YaoX.YangQ.XiangM.YanM.ZhuZ.Identification of novel serum biomarkers for gastric cancer by magnetic bead20102961971KleinA.Human total serum N-glycome20084651852-s2.0-5384912684510.1016/S0065-2423(08)00402-2